Sunil Patel, DO
Nephrology · Apple Valley, CANPI 1134274012
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $334,841 of the $508,522 with a category attached, or 65.8%. 45 manufacturers reported payments, led by Amgen at 55.9% of the total. 2025 is the largest year on record at $145,997, 7.4 times the $19,769 reported in 2019. Among nephrology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,202 payments — averaging $423.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$284K
- Akebia Therapeutics Inc$90K
- GSK$47K
- Bayer$35K
- AstraZeneca$31K
- Calliditas Therapeutics US Inc.$7K
- plus $15K from 39 others
Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$150
What the payments were for
- Consulting fees$36,0807%
- Speaking & faculty fees$334,84166%
- Travel & lodging$115,04723%
- Food & beverage$22,3854%
- Education$1690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$508,522 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KrystexxaPegloticase | 99 | $5,413,334 |
| KerendiaFinerenone | 244 | $204,270 |
| RayaldeeCalcifediol | 138 | $203,197 |
| FarxigaDapagliflozin Propanediol | 292 | $194,546 |
| XphozahTenapanor Hcl | 61 | $177,757 |
| LupkynisVoclosporin | 12 | $177,210 |
| AuryxiaFerric Citrate | 108 | $169,868 |
| VelphoroSucroferric Oxyhydroxide | 33 | $120,800 |
| TrulicityDulaglutide | 104 | $117,376 |
| LokelmaSodium Zirconium Cyclosilicate | 135 | $106,884 |
| OzempicSemaglutide | 105 | $104,252 |
| JardianceEmpagliflozin | 136 | $97,665 |
| MounjaroTirzepatide | 74 | $88,644 |
| DapagliflozinDapagliflozin Propanediol | 143 | $72,732 |
| EliquisApixaban | 105 | $67,189 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa | $284,433 | $5,413,33499 claims |
| AstraZenecaFarxiga, Lokelma | $30,861 | $301,429427 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $281 | $206,020178 claims |
| BayerKerendia | $35,272 | $204,270244 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $659 | $203,197138 claims |
| Aurinia Pharma U.S., Inc.Lupkynis | $258 | $177,21012 claims |
| Akebia Therapeutics IncAuryxia | $89,576 | $169,868108 claims |
| Fresenius USA Marketing, Inc.Velphoro | $44 | $120,80033 claims |
| Novo NordiskOzempic, Rybelsus | $621 | $114,919117 claims |
| Boehringer IngelheimJardiance | $484 | $97,665136 claims |
| MerckJanuvia, Verquvo | $752 | $87,579122 claims |
| PfizerEliquis | $75 | $67,189105 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,341 nephrology providers in California.
Other nephrology in Apple Valley
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Suphamai BunnapradistLos Angeles$498K
- Mohammad KamgarLos Angeles$497K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.